BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

878 related articles for article (PubMed ID: 28733097)

  • 21. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
    Meinhofer A; Williams AR; Johnson P; Schackman BR; Bao Y
    J Subst Abuse Treat; 2019 Oct; 105():37-43. PubMed ID: 31443889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
    Cremer LJ; Board A; Guy GP; Schieber L; Asher A; Parker EM
    Drug Alcohol Depend; 2022 Mar; 232():109192. PubMed ID: 35065513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort.
    McCann NC; LaRochelle MR; Morgan JR
    J Subst Use Addict Treat; 2024 Apr; 159():209281. PubMed ID: 38122988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
    Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
    N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.
    Shulman M; Provost S; Ohrtman K; Novo P; Meyers-Ohki S; Van Veldhuisen P; Oden N; Otterstatter M; Bailey GL; Liu D; Rotrosen J; Nunes EV; Weiss RD
    Contemp Clin Trials; 2024 Jul; 142():107543. PubMed ID: 38657730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.
    Ruglass LM; Scodes J; Pavlicova M; Campbell ANC; Fitzpatrick S; Barbosa-Leiker C; Burlew K; Greenfield SF; Rotrosen J; Nunes EV
    Drug Alcohol Depend; 2019 Dec; 205():107649. PubMed ID: 31704382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
    Kelly MM; Reilly E; Quiñones T; Desai N; Rosenheck R
    Drug Alcohol Depend; 2018 Feb; 183():111-117. PubMed ID: 29245103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross-sectional study of a state all-payer claims database.
    Simon L; Choudhary A; Ticku S; Barrow J; Tobey M
    J Public Health Dent; 2022 Sep; 82(4):461-467. PubMed ID: 34816438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
    Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
    Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
    J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does XR injectable naltrexone prevent relapse as effectively as daily sublingual buprenorphine-naloxone?
    Roe M; Wilson CG; Fusco CW; Hulkower S; Stigleman S
    J Fam Pract; 2020 Dec; 69(10):E14-E15. PubMed ID: 33348352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
    Baxley C; Borsari B; Reavis JV; Manuel JK; Herbst E; Becker W; Pennington D; Batki SL; Seal K
    Addict Behav; 2023 Apr; 139():107589. PubMed ID: 36565531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia.
    Saloner B; Landis R; Stein BD; Barry CL
    Health Aff (Millwood); 2019 Apr; 38(4):633-642. PubMed ID: 30933592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.